Barriers to and enablers of Pakistani pharmaceutical export to regulated markets: regulatory perspective
The cGMP compliance, regulatory assistance, and appropriate research and development, including bioequivalence studies, could contribute to export enhancement to SRA countries. Further, the exports from Pakistan to countries with SRAs could be enhanced with DRAP's coordination with the trade development authority of Pakistan.
Authors
- Nadeem Irfan Bukhari (ORCID: https://orcid.org/0000-0001-5710-9574)
- Arslan Javed (ORCID: https://orcid.org/0009-0000-3535-4157)
- Mobina Manzoor (ORCID: https://orcid.org/0000-0003-2832-4245)
- Fauzan akbar
- Furqan Khurshid Hashmi (ORCID: https://orcid.org/0000-0003-4921-3739)
- Fauzia Butt (ORCID: https://orcid.org/0000-0003-4952-3075)
- Nasir Abbas (ORCID: https://orcid.org/0000-0003-1862-1609)
- Gabriele De Rubis (ORCID: https://orcid.org/0000-0001-7088-396X)
- Hina Shahbaz
- Zobia Mubarak (ORCID: https://orcid.org/0009-0003-7639-1167)
- Amna Riaz (ORCID: https://orcid.org/0000-0002-7785-3162)
Institutions
- University of Technology Sydney (AU)
- Institute for Women's Policy Research (US)
- Lahore College for Women University (PK)
- University of the Punjab (PK)
- Government of Pakistan (PK)
- Qarshi University (PK)
Publication Details
- Journal
- Journal of Pharmaceutical Policy and Practice
- Published
- 2025-11-28
- DOI
- https://doi.org/10.1080/20523211.2025.2564828
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 0.00